Restructuring	12 Months Ended
Restructuring	Dec. 31, 2024
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring On August 21, 2024, the Company announced a restructuring plan to reduce the Company’s workforce by approximately 32% in response to the Company's announcement on August 20, 2024 that it planned to halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. The Company recorded a total restructuring charge of $2.6 million, which consists of one-time termination benefits such as severance costs and related benefits. For the year ended December 31, 2024, the Company made cash payments related to the restructuring of $1.1 million. As of December 31, 2024, the $1.5 million of one-time termination benefits remain payable and are recorded within the accrued liabilities and other liabilities line items on the Company's balance sheet. Restructuring payments commenced in September 2024 and will extend through March 2026.

Whitehawk Therapeutics, Inc. 10-K